Significantly, at the dose of 1 mg/kg, IGF-TRAP-3.3 had a superior therapeutic effect to that of the anti-ligand antibody (MEDI-573), now in phase II clinical trials, as assessed in the experimental colon cancer liver metastasis model (Fig. 5C). This evidence concerns the gene IGF1 and colonic neoplasm.